Literature DB >> 20652728

Polymethacrylate microparticles gel for topical drug delivery.

Hagar Ibrahim Labouta1, Labiba K El-Khordagui.   

Abstract

PURPOSE: Evaluating the potentials of particulate delivery systems in topical drug delivery.
METHODS: Polymethacrylate microparticles (MPs) incorporating verapamil hydrochloride (VRP) as a model hydrophilic drug with potential topical clinical uses, using Eudragit RS100 and Eudragit L100 were prepared for the formulation of a composite topical gel. The effect of initial drug loading, polymer composition, particularly the proportion of Eudragit L100 as an interacting polymer component and the HLB of the dispersing agent on MPs characteristics was investigated. A test MPs formulation was incorporated in gel and evaluated for drug release and human skin permeation.
RESULTS: MPs showed high % incorporation efficiency and % yield. Composition of the hybrid polymer matrix was a main determinant of MPs characteristics, particularly drug release. Factors known to influence drug release such as MPs size and high drug solubility were outweighed by strong VRP-Eudragit L100 interaction. The developed MPs gel showed controlled VRP release and reduced skin retention compared to a free drug gel.
CONCLUSION: Topical drug delivery and skin retention could be modulated using particulate delivery systems. From a practical standpoint, the VRP gel developed may offer advantage in a range of dermatological conditions, in response to the growing off-label topical use of VRP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652728     DOI: 10.1007/s11095-010-0212-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  38 in total

1.  Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration.

Authors:  S A Wissing; R H Müller
Journal:  J Control Release       Date:  2002-06-17       Impact factor: 9.776

Review 2.  Prevention and treatment of excessive dermal scarring.

Authors:  Ingrid E Roseborough; Mark A Grevious; Raphael C Lee
Journal:  J Natl Med Assoc       Date:  2004-01       Impact factor: 1.798

3.  Formulation of anastrozole microparticles as biodegradable anticancer drug carriers.

Authors:  Ahmed S Zidan; Omaima A Sammour; Mohammed A Hammad; Nagia A Megrab; Muhammad D Hussain; Mansoor A Khan; Muhammad J Habib
Journal:  AAPS PharmSciTech       Date:  2006-07-21       Impact factor: 3.246

4.  Current topical treatments in wound healing, part 1.

Authors:  Christopher D Helmke
Journal:  Int J Pharm Compd       Date:  2004 Jul-Aug

5.  Effect of emulsifier blend on the characteristics of sustained release diclofenac microspheres.

Authors:  L Lewis; R Boni; C M Adeyeye
Journal:  J Microencapsul       Date:  1998 May-Jun       Impact factor: 3.142

6.  Prevention and treatment of keloids with intralesional verapamil.

Authors:  F D'Andrea; S Brongo; G Ferraro; A Baroni
Journal:  Dermatology       Date:  2002       Impact factor: 5.366

7.  In vitro release of hydrophilic and hydrophobic drugs from liposomal dispersions and gels.

Authors:  Mohamed Mahmoud Nounou; Labiba K El-Khordagui; Nawal A Khalafallah; Said A Khalil
Journal:  Acta Pharm       Date:  2006-09       Impact factor: 2.230

8.  Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study.

Authors:  William P Fitch; W Jerry Easterling; Robert L Talbert; Michael J Bordovsky; Michael Mosier
Journal:  J Sex Med       Date:  2007-03       Impact factor: 3.802

9.  Formulation optimization of gentamicin loaded Eudragit RS100 microspheres using factorial design study.

Authors:  Deependra Singh; Swarnlata Saraf; Vinod Kumar Dixit; Shailendra Saraf
Journal:  Biol Pharm Bull       Date:  2008-04       Impact factor: 2.233

10.  Influence of methacrylic and acrylic acid polymers on the release performance of weakly basic drugs from sustained release hydrophilic matrices.

Authors:  Aditya S Tatavarti; Ketan A Mehta; Larry L Augsburger; Stephen W Hoag
Journal:  J Pharm Sci       Date:  2004-09       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.